GlassScriptPhysician profile
Annie Farley
NPI 1255037321
$3,228.83
in general payments reported to CMS, 2019-2025
26 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $853 · 2024: $1,234 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,228.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,066.40 | 2023-2025 | |
| Axsome Therapeutics, INC. | $576.87 | 2023-2025 | Sunosi, Symbravo |
| Ipsen Biopharmaceuticals, INC | $333.03 | 2023-2025 | Dysport |
| Merz Pharmaceuticals, LLC | $249.10 | 2023-2025 | Xeomin |
| Teva Pharmaceuticals USA, INC. | $142.79 | 2024-2025 | Ajovy |
| Pfizer INC. | $106.02 | 2024-2025 | |
| Genzyme Corporation | $98.02 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $94.32 | 2023-2024 | Nuedexta |
| Lundbeck LLC | $84.36 | 2023 | Vyepti |
| Sk Life Science, INC. | $68.82 | 2023-2024 | |
| Argenx US, INC. | $50.15 | 2025 | Vyvgart Hytrulo |
| Lilly USA, LLC | $47.76 | 2023-2024 | Emgality, Reyvow |
| Tonix Medicines, INC. | $33.84 | 2024 | Zembrace Symtouch |
| Jazz Pharmaceuticals INC. | $28.85 | 2024 | |
| Inspire Medical Systems, INC. | $27.78 | 2025 | Inspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $25.03 | 2023 | |
| Emd Serono, INC. | $24.91 | 2024 | |
| Boston Scientific Corporation | $22.65 | 2023 | Varithena Administration Pack |
| Impel Pharmaceuticals LLC | $22.62 | 2025 | Trudhesa |
| Acorda Therapeutics, INC | $21.92 | 2023 | Inbrija, Ampyra |
| Tg Therapeutics, INC. | $19.32 | 2023 | |
| Scilex Pharmaceuticals INC. | $18.67 | 2025 | |
| Amneal Pharmaceuticals LLC | $17.90 | 2023 | Lyvispah |
| Alexion Pharmaceuticals, INC. | $16.35 | 2023 | Soliris |
| Csl Behring | $15.69 | 2023 | Hizentra |
| Ucb, INC. | $15.66 | 2024 | Briviact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Farley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.